# Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma

> **NCT01431794** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 23 (actual)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** LDE225-600mg
- **DRUG:** Gemcitabine
- **DRUG:** nab-paclitaxel
- **DRUG:** LDE225-400mg
- **DRUG:** LDE225-800mg

## Key facts

- **NCT ID:** NCT01431794
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-12-27
- **Primary completion:** 2018-11-05
- **Final completion:** 2018-11-05
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Study was terminated due to cease in manufacturing of study drug.
- **Last updated:** 2020-01-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01431794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01431794, "Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01431794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*